AI Engines For more Details: Perplexity Kagi Labs You
Hypertension (High Blood Pressure): Cilnidipine is indicated for the treatment of hypertension. It works by blocking calcium channels in the smooth muscle cells of blood vessels, resulting in vasodilation (widening of blood vessels). This vasodilatory effect reduces peripheral vascular resistance, leading to a decrease in blood pressure. Cilnidipine is effective in lowering both systolic and diastolic blood pressure, and it may be used as monotherapy or in combination with other antihypertensive medications to achieve target blood pressure goals.
Chronic Kidney Disease (CKD) with Hypertension: Cilnidipine may be particularly beneficial for individuals with chronic kidney disease (CKD) who also have hypertension. CKD is often associated with hypertension, and controlling blood pressure is essential for preserving kidney function and reducing the risk of cardiovascular events. Cilnidipine's dual mechanism of action, which includes both L-type and N-type calcium channel blockade, may provide additional renal protection compared to other calcium channel blockers, potentially slowing the progression of CKD and reducing proteinuria (excess protein in the urine).
Vascular Protection: Cilnidipine has been shown to have beneficial effects on vascular function beyond its blood pressure-lowering effects. It may improve endothelial function, reduce arterial stiffness, and attenuate oxidative stress and inflammation within the vascular wall. These vascular protective properties may contribute to the reduction of cardiovascular events, such as heart attack and stroke, in individuals with hypertension and other cardiovascular risk factors.
Angina Pectoris: While cilnidipine is primarily indicated for hypertension, it may also be used off-label for the treatment of stable angina pectoris, a condition characterized by chest pain or discomfort due to reduced blood flow to the heart muscle. By dilating coronary arteries and improving myocardial perfusion, cilnidipine can help alleviate angina symptoms and improve exercise tolerance in individuals with stable angina.
Peripheral Arterial Disease (PAD): Cilnidipine's vasodilatory effects may benefit individuals with peripheral arterial disease (PAD), a condition characterized by narrowed or blocked arteries in the legs, leading to reduced blood flow and symptoms such as leg pain or cramping during exercise (intermittent claudication). By improving blood flow to the peripheral arteries, cilnidipine may help alleviate symptoms and improve walking distance in individuals with PAD.
Side Effects: Common side effects of cilnidipine may include peripheral edema (swelling of the legs or ankles), headache, dizziness, flushing, palpitations, and gastrointestinal disturbances. These side effects are usually mild to moderate in severity and often resolve with continued use or dose adjustment. Cilnidipine may also cause less peripheral edema compared to some other calcium channel blockers due to its dual mechanism of action.
Contraindications: Cilnidipine is contraindicated in individuals with a known hypersensitivity to the medication or any of its components, as well as those with severe hypotension (low blood pressure), cardiogenic shock, or aortic stenosis. It should be used with caution in elderly patients and those with impaired hepatic function, as well as those taking other medications that may interact with cilnidipine.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.4 | 0.4 | |
| Acne | 0.3 | -0.3 | |
| ADHD | 1.9 | 0.3 | 5.33 |
| Age-Related Macular Degeneration and Glaucoma | 0.6 | 0.4 | 0.5 |
| Allergic Rhinitis (Hay Fever) | 3.4 | 1.6 | 1.13 |
| Allergies | 4.7 | 1.4 | 2.36 |
| Allergy to milk products | 1.2 | 1.6 | -0.33 |
| Alopecia (Hair Loss) | 1.3 | 1.3 | |
| Alzheimer's disease | 4.2 | 3.9 | 0.08 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.7 | 0.7 | 2.86 |
| Ankylosing spondylitis | 3.4 | 1.5 | 1.27 |
| Anorexia Nervosa | 1.6 | 2.1 | -0.31 |
| Antiphospholipid syndrome (APS) | 0.8 | 0.3 | 1.67 |
| Asthma | 4.2 | 0.9 | 3.67 |
| Atherosclerosis | 1.8 | 0.2 | 8 |
| Atrial fibrillation | 3.2 | 1.9 | 0.68 |
| Autism | 7 | 6 | 0.17 |
| Autoimmune Disease | 1.2 | 0.5 | 1.4 |
| Barrett esophagus cancer | 0.3 | -0.3 | |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 1.9 | 1.9 | |
| Bipolar Disorder | 2.4 | 0.6 | 3 |
| Brain Trauma | 0.6 | 0.9 | -0.5 |
| Breast Cancer | 0.4 | 0.4 | |
| Cancer (General) | 1.2 | -1.2 | |
| Carcinoma | 3.5 | 2 | 0.75 |
| Celiac Disease | 1.7 | 2.7 | -0.59 |
| Cerebral Palsy | 1.1 | 0.7 | 0.57 |
| Chronic Fatigue Syndrome | 4.1 | 4.2 | -0.02 |
| Chronic Kidney Disease | 4.1 | 1.2 | 2.42 |
| Chronic Lyme | 0.6 | 0.3 | 1 |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.9 | 0.6 | 2.17 |
| Chronic Urticaria (Hives) | 1.4 | 0.6 | 1.33 |
| Coagulation / Micro clot triggering bacteria | 1.7 | 0.7 | 1.43 |
| Cognitive Function | 2.8 | 0.8 | 2.5 |
| Colorectal Cancer | 5.4 | 1.4 | 2.86 |
| Constipation | 1.6 | 0.1 | 15 |
| Coronary artery disease | 2.1 | 1 | 1.1 |
| COVID-19 | 6 | 6.2 | -0.03 |
| Crohn's Disease | 6.5 | 3.5 | 0.86 |
| Cushing's Syndrome (hypercortisolism) | 0.4 | -0.4 | |
| cystic fibrosis | 1 | 0.7 | 0.43 |
| d-lactic acidosis (one form of brain fog) | 0.4 | 0.4 | |
| deep vein thrombosis | 1.6 | 0.9 | 0.78 |
| Denture Wearers Oral Shifts | 0.9 | 0.9 | |
| Depression | 7.4 | 4.1 | 0.8 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 1.7 | 2 | -0.18 |
| Endometriosis | 3 | 1 | 2 |
| Eosinophilic Esophagitis | 0.3 | -0.3 | |
| Epilepsy | 3.2 | 1.7 | 0.88 |
| erectile dysfunction | 1.1 | 0.3 | 2.67 |
| Fibromyalgia | 2.7 | 1.3 | 1.08 |
| Functional constipation / chronic idiopathic constipation | 3.8 | 2.9 | 0.31 |
| gallstone disease (gsd) | 3.8 | 0.3 | 11.67 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.7 | 1.2 | -0.71 |
| Generalized anxiety disorder | 2.6 | 1.1 | 1.36 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 1 | 0.2 | 4 |
| Graves' disease | 1.3 | 1.9 | -0.46 |
| Gulf War Syndrome | 0.6 | 1 | -0.67 |
| Halitosis | 0.6 | 0.3 | 1 |
| Hashimoto's thyroiditis | 2.8 | 1.8 | 0.56 |
| Heart Failure | 4.3 | 0.7 | 5.14 |
| hemorrhagic stroke | 1 | 1 | |
| Hidradenitis Suppurativa | 1.2 | 1.2 | |
| High Histamine/low DAO | 1.2 | 0.6 | 1 |
| hypercholesterolemia (High Cholesterol) | 0.6 | 0.6 | |
| hyperglycemia | 1.6 | 1.1 | 0.45 |
| Hyperlipidemia (High Blood Fats) | 0.6 | 0.6 | |
| hypersomnia | 0.4 | -0.4 | |
| hypertension (High Blood Pressure | 4.4 | 3 | 0.47 |
| Hypothyroidism | 0.7 | -0.7 | |
| Hypoxia | 3.3 | 0.3 | 10 |
| IgA nephropathy (IgAN) | 1.6 | 2.3 | -0.44 |
| Inflammatory Bowel Disease | 6.5 | 4.6 | 0.41 |
| Insomnia | 1.9 | 1.3 | 0.46 |
| Intelligence | 1.3 | 1.3 | |
| Intracranial aneurysms | 1.2 | 1.2 | |
| Irritable Bowel Syndrome | 5.1 | 2.7 | 0.89 |
| ischemic stroke | 2.2 | 0.9 | 1.44 |
| Liver Cirrhosis | 5.3 | 2.6 | 1.04 |
| Long COVID | 3.7 | 4.4 | -0.19 |
| Low bone mineral density | 0.3 | -0.3 | |
| Lung Cancer | 1 | 1 | 0 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 0.9 | 0.6 | 0.5 |
| ME/CFS with IBS | 0.5 | 1.4 | -1.8 |
| ME/CFS without IBS | 1.8 | 2 | -0.11 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.3 | 0.3 | |
| Metabolic Syndrome | 5.6 | 4.4 | 0.27 |
| Mood Disorders | 6.9 | 3.8 | 0.82 |
| multiple chemical sensitivity [MCS] | 0.9 | 0.1 | 8 |
| Multiple Sclerosis | 5.9 | 4.6 | 0.28 |
| Multiple system atrophy (MSA) | 0.6 | 0.7 | -0.17 |
| myasthenia gravis | 0.9 | 0.2 | 3.5 |
| neuropathic pain | 0.3 | 1.4 | -3.67 |
| Neuropathy (all types) | 0.7 | 1 | -0.43 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.7 | 0.7 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 3.2 | 2 | 0.6 |
| NonCeliac Gluten Sensitivity | 1 | 0.6 | 0.67 |
| Obesity | 5.9 | 5.5 | 0.07 |
| obsessive-compulsive disorder | 5 | 2.8 | 0.79 |
| Osteoarthritis | 2.7 | 1.2 | 1.25 |
| Osteoporosis | 1.7 | 1.3 | 0.31 |
| pancreatic cancer | 0.3 | 0.3 | 0 |
| Parkinson's Disease | 6.4 | 3.8 | 0.68 |
| Polycystic ovary syndrome | 6 | 2.1 | 1.86 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.3 | -0.5 |
| Premenstrual dysphoric disorder | 0.4 | 0.4 | 0 |
| primary biliary cholangitis | 0.9 | 1 | -0.11 |
| Primary sclerosing cholangitis | 1.8 | 2.9 | -0.61 |
| Psoriasis | 2.4 | 1.3 | 0.85 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 5 | 2.1 | 1.38 |
| Rosacea | 1.2 | 0.2 | 5 |
| Schizophrenia | 4 | 1.9 | 1.11 |
| scoliosis | 0.4 | 1.2 | -2 |
| Sjögren syndrome | 1.4 | 2.2 | -0.57 |
| Sleep Apnea | 1.6 | 1 | 0.6 |
| Slow gastric motility / Gastroparesis | 1 | 0.3 | 2.33 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.1 | 0.1 | 10 |
| Stress / posttraumatic stress disorder | 2.2 | 1.4 | 0.57 |
| Systemic Lupus Erythematosus | 3.7 | 1.1 | 2.36 |
| Tic Disorder | 0.7 | 0.9 | -0.29 |
| Tourette syndrome | 0.9 | 0.3 | 2 |
| Type 1 Diabetes | 2.8 | 2.2 | 0.27 |
| Type 2 Diabetes | 5.5 | 4.6 | 0.2 |
| Ulcerative colitis | 4.9 | 3.8 | 0.29 |
| Unhealthy Ageing | 4.3 | 0.7 | 5.14 |
| Vitiligo | 2.5 | 0.9 | 1.78 |
